ArticleBMC microbiology2025
Deciphering the efficacy of staphyloxanthin-encapsulated niosomal nanovesicles to attenuate biofilm formation, quorum sensing, and meropenem persistence in Acinetobacter baumannii.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- ThebioRxiv : the preprint server for biology · 2026Article
- Liposome drug delivery strategies: state-of-the-art for combating bacterial biofilms.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcinetobacter baumannii is the primary cause of persistent opportunistic infections in healthcare settings, recognized as a global priority due to its resistance to antibiotic therapy. Quorum sensing and biofilm formation are the key factors driving the pathogenesis and drug resistance of A. baumannii. Nanostructures demonstrated encouraging promise in enhancing the therapeutic efficacy and overcoming treatment failure. Therefore, the efficacy of staphyloxanthin (STX)-encapsulated niosomes was evaluated both in vitro and in vivo.
resultsThe formulated niosomal nanovesicles displayed a spherical shape at the nanoscale (177.8 nm), featuring a slow-release rate (39.6%) and appropriate entrapment efficiency (92.7%). Our results demonstrated that STX exhibited strong antibacterial activity, with MIC values up to 16 µg/mL against multidrug-resistant isolates (n = 24). The in vitro findings revealed that the encapsulation of STX within niosomal nanovesicles demonstrated superior therapeutic efficacy compared to the free solution. This improvement was reflected by a significant reduction in biofilm formation (68-88%), motility (66.66-94.45%), and siderophore production (48.75-79.5%), as well as marked disruption of the mature biofilm by 82%. The anti-quorum sensing activity of STX was further confirmed the attenuation of biofilm and virulence, as evidenced by downregulation of abaI expression (1.42-fold reduction) and molecular docking simulations. It is noteworthy that the biological findings revealed a significant eradication of meropenem-induced persister cells after the addition of niosomal dispersion. The preclinical investigations prove the efficacy of STX in improving survival rates through reducing the bacterial burden (2-fold reduction) and lethal inflammatory consequences in a mouse model of pneumonia.
conclusionour results suggested that STX may serve as a promising alternative for combating A. baumannii biofilms and persister cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.